OncoMatch/Clinical Trials/NCT06785636
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Is NCT06785636 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including Pocenbrodib and Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617 for mcrpc (metastatic castration-resistant prostate cancer).
Treatment: Pocenbrodib · Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617 — This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration-resistant prostrate cancer (mCRPC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Prostate Cancer
Disease stage
Metastatic disease required
Prior therapy
Cannot have received: chemotherapy
Intervention with any chemotherapy, investigational agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Screening or 5 half-lives from the last dose (whichever is shorter)
Cannot have received: investigational agent
Intervention with any chemotherapy, investigational agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Screening or 5 half-lives from the last dose (whichever is shorter)
Cannot have received: other anticancer drug (enzalutamide, apalutamide, darolutamide)
Intervention with any chemotherapy, investigational agent, or other anticancer drug, including enzalutamide, apalutamide, or darolutamide, 14 days prior to Screening or 5 half-lives from the last dose (whichever is shorter)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MemorialCare Orange Coast Medical Center · Fountain Valley, California
- University of Colorado Health · Aurora, Colorado
- Mount Sinai Medical Center · Miami, Florida
- Karmanos Cancer Institute · Detroit, Michigan
- Siteman Cancer Center · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify